For a post‑stroke patient with persistent headache and neuropathic arm pain, how do amitriptyline, lamotrigine, and gabapentin compare in terms of efficacy, dosing, and side‑effect profile?

Post-Stroke Neuropathic Pain: Amitriptyline vs. Lamotrigine vs. Gabapentin

For a post-stroke patient with persistent headache and neuropathic arm pain, start with amitriptyline 75 mg at bedtime as first-line therapy, with lamotrigine as an equally reasonable alternative if anticholinergic side effects are prohibitive; reserve gabapentin as second-line treatment.

First-Line Treatment Hierarchy

The 2016 American Heart Association/American Stroke Association guidelines explicitly designate amitriptyline and lamotrigine as reasonable first-line pharmacological treatments (Class IIa, Level B) for central post-stroke pain 1. In contrast, gabapentin is relegated to second-line status (Class IIb, Level B) 1. This distinction is critical—the guidelines make clear that gabapentin "has not been well studied for poststroke central pain" despite effectiveness in other neuropathic conditions 1.

Efficacy Comparison

Amitriptyline demonstrates the strongest evidence:

• 75 mg at bedtime has been shown to lower daily pain ratings and improve global functioning 1
• A landmark placebo-controlled trial showed statistically significant pain reduction with 10 of 15 patients (67%) responding to treatment 2
• Pain relief occurs within 2 weeks, independent of antidepressant effects 2

Lamotrigine shows moderate efficacy:

• 200 mg daily reduces median pain scores from 7 to 5 (p=0.01) 3
• Only 44% of patients achieve good clinical response 1—notably lower than amitriptyline
• Particularly effective for cold-induced pain and allodynia 1, 3
• No effect at lower doses (25-100 mg); requires full 200 mg dose 3

Gabapentin has limited post-stroke evidence:

• No dedicated placebo-controlled trials for central post-stroke pain 1
• Evidence extrapolated from other neuropathic pain conditions 1
• Recent comparative data suggests gabapentin may have fewer adverse effects than pregabalin or amitriptyline in general neuropathic pain 4, but this doesn't override stroke-specific guidelines

Dosing Protocols

Amitriptyline

• Start: 10-25 mg nightly 5
• Titrate: Increase every 3-5 days as tolerated 5
• Target: 75 mg at bedtime (proven effective dose) 1, 2
• Maximum: 50-150 mg nightly 5
• Time to effect: 1-2 weeks 2

Lamotrigine

• Start: 25 mg daily
• Titrate: Slowly over 8 weeks to minimize rash risk 3
• Target: 200 mg daily (only effective dose) 3
• Critical: Lower doses (25-100 mg) are ineffective 3
• Time to effect: 8 weeks to reach therapeutic dose 3

Gabapentin (Second-Line)

• Start: 100-300 mg nightly 5, 6
• Titrate: Increase by 50-100% every few days 5
• Target: 900-3600 mg daily in 2-3 divided doses 5, 6
• Adjust: Reduce dose in renal insufficiency 5, 7
• Time to effect: 2+ months for adequate trial 6

Side Effect Profiles

Amitriptyline (Tertiary Amine TCA)

Common anticholinergic effects 5:

• Sedation (useful if insomnia present)
• Dry mouth
• Urinary hesitancy/retention
• Constipation
• Orthostatic hypotension

Critical pitfall: These side effects are more pronounced than with secondary amine TCAs (nortriptyline, desipramine), but amitriptyline may be more efficacious 5. In elderly or post-stroke patients with cardiac issues, consider switching to nortriptyline if side effects are intolerable.

Lamotrigine

Generally well-tolerated 3:

• Few and transient side effects
• Rash risk: 2 mild rashes in 30 patients (7%), one requiring withdrawal 3
• Slow titration minimizes rash risk
• No significant anticholinergic burden

Gabapentin

CNS effects predominate 7:

• Somnolence (21% vs 5% placebo)
• Dizziness (28% vs 8% placebo)
• Ataxia
• Driving impairment warning: FDA label specifically warns about significant driving impairment 7
• Peripheral edema
• Weight gain

Advantage: Minimal drug interactions, no anticholinergic effects 7

Clinical Decision Algorithm

1. Start with amitriptyline 75 mg at bedtime unless:

   • Elderly with fall risk → consider lamotrigine
   • Cardiac conduction abnormalities → use lamotrigine
   • Urinary retention/BPH → use lamotrigine
   • Severe anticholinergic intolerance → use lamotrigine

2. If amitriptyline fails or is not tolerated:

   • Switch to lamotrigine 200 mg daily (requires 8-week titration)
   • Do NOT use lower lamotrigine doses—they are ineffective 3

3. If both first-line agents fail:

   • Add gabapentin 900-3600 mg daily as second-line 1
   • Consider combination therapy (not well-studied but used clinically)

4. Monitor response:

   • Use standardized pain diaries, visual analog scales, or pain questionnaires 1
   • Assess weekly during titration
   • Allow adequate trial: 4-6 weeks at target dose before declaring failure

Critical Caveats

Lamotrigine's 44% response rate 1 means more than half of patients will not achieve adequate relief—this is substantially lower than amitriptyline's 67% response rate 2. However, lamotrigine's superior tolerability makes it a reasonable first choice in patients where anticholinergic effects pose significant risk.

Gabapentin's second-line status is based on lack of stroke-specific evidence, not proven inefficacy 1. The Canadian guidelines actually suggest gabapentin/pregabalin as first-line 8, but this contradicts the more authoritative and recent AHA/ASA recommendations.

Combination therapy with antidepressants plus anticonvulsants is mentioned in cancer pain guidelines 5 but lacks specific evidence in post-stroke pain. Consider this approach only after monotherapy failures.

Renal function matters: Both gabapentin and pregabalin require dose adjustment in renal insufficiency 5, 6, 7—critical in stroke patients who may have vascular disease affecting kidney function.